FOLH1 and glioma: In this scenario, if confirmed in future trials, PSMA-based PET/CT could potentially play a role in assessing response to anti-angiogenic therapy, such as bevacizumab, in delineating tumor regions most sensitive to external beam radiotherapy and in identifying glioma patients suitable for targeted [177Lu]Lu-PSMA therapy.